[논문]Developing an Improved Risk-Adjusted Net Present Value Technology Valuation Model for the Biopharmaceutical Industry

Woo, Jonghak; Kim, Eungdo; Sung, Tae-Eung; Lee, Jongtaik; Shin, Kwangsoo; Lee, Jeonghee

doi:10.3390/joitmc5030045

Developing an Improved Risk-Adjusted Net Present Value Technology Valuation Model for the Biopharmaceutical Industry 원문보기

Journal of open innovation : technology, market, and complexity, v.5 no.3, 2019년, pp.45 -

Woo, Jonghak , Kim, Eungdo , Sung, Tae-Eung , Lee, Jongtaik , Shin, Kwangsoo , Lee, Jeonghee

Abstract ▼ AI-Helper

The financial valuation of a drug that is still under development is required for various purposes. The risk-adjusted net present value (r-NPV) method, which recently emerged in the biotech industry, uses the development attrition rate as a discount factor to reflect risk during each development phase. The r-NPV method was developed to overcome the disadvantages of the prevailing discounted cash flow and real options methods and considers drug type, as well as the stage of development in its approach. Using this method, the current study examines technology values in the biopharmaceutical industry and matches the clinical development periods and success rates of these new drugs by analyzing datasets from ClinicalTrials.gov and MedTrack DB. It thus provides support for an empirical valuation model for experts in the field. Notably, there is limited research on the attrition rate and development period of new substance drugs and the research results are not consistently presented. In addition to new substance drugs, further research is necessary to deepen understanding of the attrition rate and development period of biologically-based drugs because of their inherent physical and developmental differences. Similarly, research on performance specifics within drug class models would enable refinement of the model.

참고문헌 (29)

Sustainability Lee 10 2018 Factors affecting pricing in patent licensing contracts in the biopharmaceutical industry
J. Open Innov. Technol. Mark. Complex. Lee 4 2018 Evaluating determinant priority of license fee in biotech industry
Deloitte Health Care Consumer Engagement No. “One-Size-Fits-All” approach Available online: https://www2.deloitte.com/content/dam/Deloitte/us/Documents/life-sciences-health-care/us-dchs-consumer-engagement-healthcare.pdf (accessed on 2 December 2018)
N. Borshell T. Ahmed Approaches to Valuation of Pharmaceutical Licensing Deals Available online: http://files.pharmadeals.net/contents/Sample_Valuation.pdf (accessed on 1 March 2018)
Mergermarket Global and regional M&A: 2014 Available online: https://www.mergermarket.com/assets/MergermarketTrendReport.2014.LegalAdvisorLeagueTables.pdf (accessed on 31 December 2018)
Bogdan 2010
Sustainability Shin 10 2018 10.3390/su10082787 Structural relationship and influence between open innovation capacities and performances

상세보기
Knowl. Manag. Res. Pract. Yun 16 305 2018 10.1080/14778238.2018.1471328 Harnessing the value of open innovation: Change in the moderating role of absorptive capability

상세보기
J. Clin. Oncol. Trotta 29 2266 2011 10.1200/JCO.2010.34.1248 Evaluation of oncology drugs at the European Medicines Agency and US Food and Drug Administration: When differences have an impact on clinical practice

상세보기
Pharmacoeconomics Grabowski 20 11 2002 10.2165/00019053-200220003-00002 Returns of research and development for 1990s new drug introductions

상세보기
Manag. Decis. Econ. DiMasi 28 285 2007 10.1002/mde.1341 The cost of biopharmaceutical R&D: Is biotech different?

상세보기
Innov. Manag. Policy Pract. Hwang 11 279 2009 10.5172/impp.11.3.279 Factors affecting open technological innovation in open source software companies in Korea

상세보기
J. Open Innov. Technol. Mark. Complex. Lee 2 1 2016 10.1186/s40852-016-0041-0 Valuations using royalty data in the life sciences area-focused on anticancer and cardiovascular therapies

상세보기
J. Open Innov. Technol. Mark. Complex. Lee 2 21 2016 10.1186/s40852-016-0047-7 Valuation method by regression analysis on real royalty-related data by using multiple input descriptors in royalty negotiations in life science area-focused on Anticancer Therapies

상세보기
Eval. Program Plan. Kim 63 18 2017 10.1016/j.evalprogplan.2017.02.012 Development of an evaluation framework for publicly funded R&D projects: The case of Korea’s next generation network

상세보기
Clin. Pharmacol. Ther. DiMasi 87 272 2010 10.1038/clpt.2009.295 Trends in risks associated with new drug development: success rates for investigational drugs

상세보기
Yourgenome How Are Drugs Designed and Developed? Available online: https://www.yourgenome.org/facts/how-are-drugs-designed-and-developed (accessed on 26 April 2018)
J. Pharm. Financ. Econ. Policy Abrantes-Metz 14 19 2004 10.1300/J371v14n04_03 Pharmaceutical development phases: A duration analysis
Nat. Biotechnol. Hay 32 40 2014 10.1038/nbt.2786 Clinical development success rates for investigational drugs

상세보기
Clinical Development Success Rates 2006-2015 Available online: https://www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf (accessed on 26 April 2018)
F. Källgren Finding the Value of Biotechnology-A Risk-Adjusted Net Present Value Approach Available online: https://www.ibg.uu.se/digitalAssets/162/c_162804-l_3-k_rapport-fredrik-kallgren.pdf (accessed on 26 April 2018)
J. Food Drug Anal. Ku 23 595 2015 10.1016/j.jfda.2015.04.008 Recent trends in specialty pharma business model Author links open overlay panel

상세보기
P. Young Biotech Financial and M&A Trends-Two Steps Forward, One Step Back Available online: http://www.pharmexec.com/biotech-financial-and-ma-trends-two-steps-forward-one-step-back (accessed on 5 March 2018)
Sustainability Kim 10 2018 How an open innovation strategy for commercialization affects the firm performance of Korean healthcare IT SMEs
J. Financ. Griffin 57 2317 2002 10.1111/1540-6261.00497 Book-to-market equity, distress risk, and stock returns

상세보기
Bus. Strategy Rev. Dimson 11 1 2000 10.1111/1467-8616.00133 Risk and return in the 20th and 21th centuries

상세보기
Sustainability Cappa 8 2016 10.3390/su8121341 How to deliver open sustainable innovation: An integrated approach for a sustainable marketable product

상세보기
Nat. Rev. Drug Discov. Smietana 15 379 2016 10.1038/nrd.2016.85 Trends in clinical success rates

상세보기
Eur. J. Innov. Manag. Chiesa 12 25 2009 10.1108/14601060910928166 Performance measurement of research and development activities

상세보기

LOADING...

원문 보기

AccessON 원문보기

원문 URL 링크

DOI : 10.3390/joitmc5030045 [무료]
Molecular Diversity Preservation International : 저널 > 논문 [무료]
Elsevier : 저널
AccessON : 저널

*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.

오픈액세스(OA) 유형

GOLD

오픈액세스 학술지에 출판된 논문

내보내기 메뉴

내보내기 구분

파일저장
인쇄
메일전송

구성항목

기본정보
상세정보

관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관

저장형식

Text(ASCII format)
Excel format
RefWorks Direct Export
RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley

메일정보

받는사람 (필수): @
보내는사람 (선택): @
제목
내용: KISTI 검색결과 이메일 서비스

안내

총 건의 자료가 검색되었습니다.

다운받으실 자료의 인덱스를 입력하세요. (1-10,000)

검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다.

데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요)

다운로드 파일은 UTF-8 형태로 저장됩니다.
파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오.

Text(ASCII format)
Excel format

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

AI-Helper ※ AI-Helper는 을 사용합니다.

AI-Helper

안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

연합인증